Formulating therapeutic molecules in nanocarriers to yield nanomedicines is an attractive approach to improve the therapeutic index of oncology drugs. Over the last three decades, the development of cancer nanomedicines has resulted in thousands of publications and several approved drug products for the treatment of solid and hematological malignancies. In the context of solid tumors, the **enhanced permeability and retention (EPR) effect** has become an important driver of cancer nanomedicine design and it has served as a key cornerstone of tumor-targeted drug delivery [@B1]-[@B3].

Recently, however, **the importance and the existence of the EPR effect** in human patients have been heavily debated [@B4]-[@B6]. It has been demonstrated that the mechanism by which nanoparticles enter solid tumors is more complex than previously thought (potentially going beyond simple extravasation through gaps in the endothelial lining) [@B7], and that immune cells in the tumor microenvironment play important roles in nanomedicines\' accumulation, retention and intratumoral distribution [@B8],[@B9]. In addition, it is clear that the EPR effect is significantly more pronounced in the small animal xenograft tumor models which are typically used to evaluate cancer nanomedicines in preclinical settings as compared to tumor growing in humans [@B10]. Accumulation of nanocarriers in human tumors definitely does occur [@B11], but the extent varies heavily between patients and tumor types. Accordingly, quantifying the degree of EPR effect in tumors using non-invasive imaging is a promising approach to stratify patients for cancer nanomedicine treatment [@B12],[@B13]. Moreover, strategies are needed to improve the effectiveness of nanomedicine therapy. This can be done *via* pharmacological and physical co-treatments to prime tumors for improved delivery and efficacy, *via* active targeting, *via* the use of multi-stage and/or stimuli-responsive nanocarrier materials, and *via* the combination of nanotherapeutics with immunotherapy [@B14], which has already shown initial clinical success [@B15]. In this virtual special issue of Theranostics, 24 research and review articles are compiled which discuss approaches aimed at improving the therapeutic efficacy of cancer nanomedicine. These strategies by themselves, and especially when combined with others, will improve cancer nanomedicine\'s clinical translation and ultimately improve patient outcomes [@B16]-[@B18].

Traditionally, EPR-mediated tumor accumulation is proposed to result from long-circulating nanoparticles with a hydrodynamic diameter size exceeding the renal clearance threshold, which can extravasate from leaky tumor vessels. However, recent studies have investigated approaches to **extend the conventional concept of EPR-based tumor targeting**. For example, Liu *et al.* describe the potential of exploring transcytosis for tumor targeting, which is a potential additional mechanism to mediate tumor targeting by nanomedicines, especially in highly stromal solid tumors such as pancreatic ductal adenocarcinoma with weak EPR effect [@B19]. Bort and colleagues discuss studies on the use of ultrasmall nanoparticles for tumor targeting. These include polysiloxane-based nanoparticles with a hydrodynamic diameter of approximately 4 nm, which have been successfully tested in animal models and have recently entered a clinical trial for treating patients with brain metastases [@B20]. In a comparative study, Xu *et al.* investigate the tumor targeting efficiency of ligand-modified nanoparticles of 3 and 30 nm, respectively. Their results show that functionalizing 3 nm nanoparticles with a targeting ligand increased tumor targeting efficiency and tumor penetration while this was not the case for 30 nm nanoparticles [@B21].

To improve the EPR effect and nanomedicine effectiveness, **pharmacological and physical co-treatments** have been employed to prime the tumor microenvironment. Kwon and colleagues summarize features of the tumor microenvironment that impair EPR-based tumor targeting by nanomedicines. In addition, several priming strategies to improve EPR effect are discussed, including physical and physiological measures to remodel the tumor microenvironment [@B22]. Dhaliwal and Zheng focus on the applications of physical strategies to improve EPR effect of tumors including ultrasound and hyperthermia. The authors also summarize assessment methods and proper use of animal models to study EPR-mediated nanomedicine targeting [@B23]. Among the physical strategies, Duan *et al*. discuss the applications of micro/nanobubbles to augment the thermal effect, acoustic streaming and cavitation mechanisms of ultrasound to enhance the EPR effect [@B24]. Recognizing the importance of the vasculature in tumor development, Tsioumpekou *et al.* demonstrate that specific suppression of PDGFRβ kinase activity by 1-NaPP1 effectively modulates the tumor microenvironment by inhibiting angiogenesis [@B25].

**Active targeting** can be used as a complementary strategy to EPR-based passive targeting to improve nanomedicine tumor accumulation and retention. Tumor targeting ligands include antibodies, fragments of antibodies (e.g. nanobodies) and peptides. Dammes and Peer summarize the applications of monoclonal antibodies in molecular imaging of cancer, autoimmune disorders and cardiovascular diseases [@B26]. In addition, the potential of using monoclonal antibody-based molecular imaging strategies in theranostics and precision medicine is highlighted. Oliveira and co-workers utilize epidermal growth factor receptor (EGFR)-targeted nanobodies to deliver photosensitizers to tumors for photodynamic therapy. Both monovalent nanobodies and biparatopic nanobodies are conjugated with photosensitizers. Although these two types of conjugates exhibit different biodistribution profiles, they result in similar levels of necrosis after photodynamic therapy, resulting in tumor reduction [@B27]. Minko and colleagues report on the use of a synthetic luteinizing hormone-releasing hormone (LHRH) decapeptide for targeting lung cancer to deliver paclitaxel and siRNAs *via* nanostructured lipid nanoparticles. The nanomedicine was administered *via* inhalation which also showed efficient homing to target cells [@B28]. Zhong and colleagues utilize cyclic RGD as a targeting ligand to improve the delivery of disulfide-crosslinked iodine-rich polymersomes to B16 melanoma. The actively targeted polymersomes exhibit an *in vivo* elimination half-life of 6.5 h in the blood circulation, thus achieving efficient tumor targeting (6.7 %ID/g) and displaying promising therapeutic efficacy [@B29].

Another strategy to improve cancer therapy is to employ **nanomedicine-based combination treatments**. Zhao *et al.* discuss the potential of this approach for the treatment of glioblastoma, benefiting from synergistic combinations of different therapeutic agents. The authors discuss the rationale of nanomedicine-based drug combinations and recent clinical progress in nanocarrier-based combination therapies [@B30]. Yu *et al.* discuss a special class of nanomedicines which induce cancer starvation by anti-angiogenesis and vascular blockade [@B31]. Such nano-interventions have been combined with other modalities such as chemotherapy, gene therapy and photodynamic therapy to achieve synergistic effects for cancer treatment. Zhu *et al.* report on a pH-sensitive nanomedicine formulation combining an enzyme, focused ultrasound-based tumor ablation and hypoxia alleviation to potentiate doxorubicin-based chemotherapy [@B32]. Their catalase-loaded nanoparticles were able to increase oxygen levels in tumors by converting H~2~O~2~ to O~2~, which improved the effect of ultrasound ablation and reduced tumor hypoxia, and these effects together improved doxorubicin efficacy.

In addition to conventional nanocarriers used for EPR-based tumor targeting, new carriers based on **bio-inspired design and materials allowing for tumor-selective drug release** have been exploited. Wolfram and co-workers review the use of extracellular vesicle-based drug delivery systems [@B33]. The intrinsic tissue tropism of extracellular vesicles is highly promising for tumor targeting and the authors summarize methods to load therapeutic agents in extracellular vesicle, and modification strategies to improve their tumor targeting ability. Mi summarizes nanomedicines with stimuli responsiveness for tumor targeted imaging, therapy and theranostics [@B34]. Nanomedicines sensitive to endogenous and exogenous stimuli as well as their potential to improve therapeutic efficacy are discussed.

Cancer nanomedicines have been extensively combined with **immunotherapy** to improve treatment outcomes. Yu and colleagues summarize the recent progress of combination nano-immunotherapy, with a special focus on nanomedicines modulating the tumor immune microenvironment (TIME) to improve immunotherapeutic efficacy [@B35]. An experimental report by Panagi *et al.* describes an immunomodulatory nanomedicine based on liposomes co-loaded with a transforming growth factor beta inhibitor and an immunogenic cell death inducer [@B36]. The liposome-based combination treatment improves the immunogenicity of triple-negative breast tumors and potentiates the efficacy of checkpoint blockade antibodies.

**Imaging** is instrumental in tumor targeting and translational cancer nanomedicine, as it can help capture tumor targeting efficiency and the heterogeneity of the EPR effect in tumors. Miller, Weissleder and colleagues comprehensively review the advances in image-guided systems pharmacology of cancer nanomedicines [@B37]. Recent developments of quantitative imaging technologies and their applications in systems pharmacology of nanomedicine are discussed, with a focus on utilizing computational modeling to understand and guide the manipulation of the EPR effect and tumor microenvironment for improving nanomedicine therapy. Dasgupta, Lammers *et al*. summarize the value of imaging-assistance in determining nanomedicine biodistribution, target site accumulation and drug release [@B38]. Imaging techniques to eventually enable patient stratification *via* companion nanodiagnostics, *via* nanotheranostics, *via* conventional imaging techniques and *via* immunohistochemistry are discussed. A comprehensive review by De Maar, Deckers and colleagues addresses multiscale imaging techniques for analyzing the heterogeneity of nanomedicines\' spatial distribution in tumors, which is an important - and often overlooked - reason for inefficient nanotherapy [@B39]. The authors summarize the applications as well as the strengths and weaknesses of 3 classes of imaging techniques for assessing the intratumoral distribution of nanomedicines, *i.e.* non-invasive clinical imaging modalities (nuclear imaging, magnetic resonance imaging, computed tomography and ultrasound), optical imaging and mass spectrometry imaging. Moss and co-workers provide novel insight on the use of high-resolution *ex vivo* micro-computed tomography for studying the spatial distribution of liposomes in 4 different tumor models [@B40]. Their work identifies vessel distribution and vessel support as crucial determinants of efficient liposome accumulation and distribution in tumors. Qi *et al.* report on the use of hyaluronic acid conjugated with fluorescent dyes for molecular imaging of pancreatic cancer in settings allowing for intraoperative imaging [@B41]. Their results demonstrate that the molecular weight of hyaluronic acid and the physicochemical properties of conjugated dyes affect the efficiency of tumor-specific imaging. Finally, Goos *et al.* report on star polymers chelated with MRI contrast agents and radioisotopes for molecular imaging and endoradiotherapy of cancerous lesions *via* exploiting EPR-based tumor accumulation. In CT26 tumor-bearing mice, the star polymer-based nanoparticles demonstrated a very high tumor targeting efficiency (15-22 %ID/g), which contributed to the improved survival of mice upon endoradiotherapy intervention [@B42].

Altogether, this **Theranostics special issue** presents a timely and comprehensive collection of research and review articles focusing on the EPR effect and beyond. These articles summarize from various different angles our current understanding of nanomedicine-based tumor targeting, and they provide valuable expert perspectives on how to improve the use and the efficacy of (EPR-based) nanomedicine formulations for cancer therapy.

[^1]: Competing Interests: The authors have declared that no competing interest exists.
